Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation

Phase 1 Completed 18 enrolled Seigo Nishida Florida Department of Health · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate feasibility and safety of the adoptive transfer of activated natural killer (NK) cells extracted from cadaveric donor liver graft perfusate for liver transplant recipients with hepatocellular carcinoma (HCC)

Timeline

Start: 2010-06
Primary completion: 2014-12
Completion: 2014-12

Publications

Ohira M, Hotta R, Tanaka Y, Matsuura T, Tekin A, Selvaggi G, Vianna R, Ricordi C, Ruiz P, Nishida S, Tzakis AG, Ohdan H. Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma. Cancer Immunol Immunother. 2022 Mar;71(3):589-599. doi: 10.1007/s00262-021-03005-3. Epub 2021 Jul 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Liver NK cells	Cell therapy	1e+07 cells	Intravenous
Subject	Liver NK cells	Cell therapy	1e+08 cells	Intravenous
Subject	Liver NK cells	Cell therapy	1e+09 cells	Intravenous

Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation

Summary

Timeline

Publications

Drugs

Indications